Inhibition of stress activated protein kinase (SAPK) pathway and sensitization of cells to cancer therapies
US6579856B2 · kind B2 · utility
14Cited by
0References
8Claims
0Family size
Inventor
Key dates
| Filing date | Sep 12, 2001 |
| Grant date | Jun 17, 2003 |
| Priority date | — |
| Expiry date | Sep 12, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions that can be administered to an individual and inhibit a stress activated protein kinase pathway. The invention also provides methods of increasing the sensitivity of cancer cells to a cancer therapy by contacting the cancer cells with a stress activated protein kinase pathway inhibitor. The invention further provides methods of reducing the severity of a cancer in a patient by administering to the patient a stress activated protein kinase pathway inhibitor and treating the patient with a conventional cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.